| 曾晓微,朱绍兴.转移性激素敏感性前列腺癌系统性全身治疗的研究进展[J].肿瘤学杂志,2019,25(11):1006-1011. |
| 转移性激素敏感性前列腺癌系统性全身治疗的研究进展 |
| Research Progress of Systemic Treatment of Metastatic Hormone-Sensitive Prostate Cancer |
| 投稿时间：2019-06-09 |
| DOI：10.11735/j.issn.1671-170X.2019.11.B016 |
|
 |
| 中文关键词: 转移性去势敏感性前列腺癌 雄激素剥夺治疗 多西他赛 阿比特龙 |
| 英文关键词:metastatic hormone-sensitive prostate cancer androgen depravation therapy docetaxel abiraterone |
| 基金项目: |
|
| 摘要点击次数: 1241 |
| 全文下载次数: 373 |
| 中文摘要: |
| 摘 要：初诊转移性前列腺癌的治疗以雄激素剥夺治疗(ADT)为主，但随着疾病进展都不可避免地发展为预后不良的转移性去势抵抗性前列腺癌。近年来，早期联合治疗在转移性激素敏感性前列腺癌的治疗方面取得了突破性进展，多项研究提示ADT联合多西他赛或醋酸阿比特龙加泼尼松龙能显著性改善患者的生存预后。同时，新药及新的治疗策略也在不断推陈出新，针对多种新型内分泌治疗及免疫治疗的探索性研究正在逐步开展。全文主要针对转移性激素敏感性前列腺癌系统性全身治疗的研究进展进行综述，探讨如何优化多种治疗选择达到患者的最大生存获益。 |
| 英文摘要: |
| Abstract：The main treatment of newly diagnosed metastatic prostate cancer(mPC) is androgen deprivation therapy(ADT). As the disease progresses，it is inevitable to develop metastatic castration-resistant prostate cancer(mCRPC) with poor prognosis. Recently，breakthroughs have been made in the treatment of metastatic hormone-sensitive prostate cancer(mHSPC)，and several studies have suggested that ADT combined with docetaxel or abiraterone acetate plus prednisolone(AAP) can significantly improve the survival prognosis of patients. Meanwhile，new drugs and new treatment strategies are constantly being introduced，and clinical trials of other hormone therapy，immunotherapy and chemotherapyect are being carried out gradually. This article reviews the advances in the systematic treatment of mHSPC and explores how to optimize multiple treatment options to achieve maximum survival benefit for patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |